Abstract:Funding Acknowledgements Type of funding sources: Public Institution(s). Main funding source(s): Biomedical Research Institute of Murcia (IMIB-Arrixaca) Introduction Hypertrophic cardiomyopathy (HCM) is the leading cause of sudden death in people under 35 years of age. (1) The variability of the phenotype together with its incomplete penetrance has been an obstacle to a complete understanding of the clinical spectrum and consequences of the disease. In recent years, there has been increasing interest in telomeric shortening and several authors have linked it to age-related diseases and HCM. (2, 3) Our aim was to study whether telomere length could affect the age at presentation and the severity of the HCM phenotype in genetic carriers. Methods Measurement of telomere length in circulating leukocytes (LTLc) was performed in 96 patients carrying a mutation in MYBPC3 causing HCM [58 affected (24 severely affected), 38 unaffected]. The variants included were c.2308+1G>A, p.Pro108Alafs*9, p.Arg891Alafs*160 and p.Glu258Lys, all considered founder mutations in our region. Peripheral venous blood samples were obtained from patients at the Inherited Heart Diseases Unit and stored at -80 oC after informed consent had been signed by all participants. For telomere length analysis, a telomeric restriction fragment (TRF) assay was performed using the TeloTAGGGTelomereLenghtAssay kit (Roche, 12209136001) according to the manufacturer's protocol with slight modifications. Results Our results show a lower LTLc in those affected patients with a more severe HCM phenotype compared to the affected and unaffected group (p=0.023) independently of age and sex, which are two variables that affect LTLc. Similarly, a shorter telomere length was associated with greater severity of the phenotype, with patients presenting a larger left atrial size (p=0.032), septal size (p=0.023) and greater obstruction (p=0.044). The presence of atrial fibrillation (p=0.039) and sudden death (p=0.024) was also higher in patients with shorter telomeres. Conclusions Telomere length is a variable that influences the expression of the phenotype in HCM patients carrying a MYBPC3 variant. This is an observation that supports the thesis of numerous publications linking HCM and other age-related diseases, sometimes called telomeropathies,(2) to telomere shortening. It has also been linked to non-hereditary conditions(3). This fact sheds some light on the complex phenotypic variability present in HCM, raising LTL as a promising prognostic biomarker of the disease, as has already been suggested by other authors.(4, 5, 6).Workflow in the telomere legth analysisClinical associations of LTLc

Telomere attrition in heart failure: a flow-FISH longitudinal analysis of circulating monocytes

Telomere length dynamics over 10-years and related outcomes in patients with COPD

Cell-free plasma telomere length correlated with the risk of cardiovascular events using machine learning classifiers

The association of telomere length and telomerase activity with adverse outcomes in older patients with non-ST-elevation acute coronary syndrome

Circulating miR-30d Predicts Survival in Patients with Acute Heart Failure.

Association between leukocyte telomere length and sex by quantile regression analysis

Precision Measurement of Telomere Length as a Future Guide to Improve CVD Interventions

Dynamics of Leukocyte Telomere Length in Patients with Fabry Disease

17-Year Follow-Up of Association Between Telomere Length and All-Cause Mortality, Cardiovascular Mortality in Individuals with Metabolic Syndrome: Results from the NHANES Database Prospective Cohort Study

Telomere Shortening in Patients on Long-Term Hemodialysis.

Longitudinal Association of Telomere Attrition with the Effects of Antihypertensive Treatment and Blood Pressure Lowering

The Association between Leucocyte Telomere Length and Survival Outcomes in Patients with Cardiovascular Disease

High Resting Coronary Flow Velocity by Echocardiography Is Associated With Worse Survival in Patients With Chronic Coronary Syndromes

The associations of leukocyte telomere length and intermediary cardiovascular phenotype with adverse cardiovascular outcomes in the white population

Telomere Length as a marker of biological aging: A critical review of recent literature.

Leukocyte Telomere Length Predicts Progression From Paroxysmal to Persistent Atrial Fibrillation in the Long Term After Catheter Ablation

Telomere Length: A Cardiovascular Biomarker and a Novel Therapeutic Target

Early biomarkers of disease in hypertrophic cardiomyopathy: does telomere length matter?

Telomere Shortening in Hypertensive Heart Disease Depends on Oxidative DNA Damage and Predicts Impaired Recovery of Cardiac Function in Heart Failure

Altered compositions of monocyte, T lymphocyte and NK cell subsets in heart failure of adult congenital heart disease

Shorter telomere length is associated with COVID-19 hospitalization and with persistence of radiographic lung abnormalities